Structure Therapeutics Inc. American Depositary Shares (GPCR)

About GPCR

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweig…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

281

Website

structuretx.com/

Fundamentals

1-day range

$46.98$49.2

Market cap

$3.44B

P/E (trailing)

—

P/E (forward)

-22.40

EPS (trailing)

$-0.91

Dividend yield

—

Beta

-1.68

Avg. volume

725.3K

Forecasts

15 analyst ratings

Structure Therapeutics Inc. American Depositary Shares Competitors

Chosen by industry and closest market cap.

• GPCR

  Structure Therapeutics Inc. American Depositary Shares

  $47.38

  ▼ 3.74%
  Market cap $3.44BP/E —
  $18.26$94.9
• TLX

  Telix Pharmaceuticals Limited American Depositary Shares

  $11.28

  ▼ 0.84%
  Market cap $3.39BP/E —
  $6.28$12.5
• ELVN

  Enliven Therapeutics Inc. Common Stock

  $57.82

  ▼ 4.43%
  Market cap $3.53BP/E —
  $14.79$62.32
• ALMS

  Alumis Inc. Common Stock

  $22.38

  ▼ 3.58%
  Market cap $3.33BP/E —
  $3.76$31.35
• ARQT

  Arcutis Biotherapeutics Inc. Common Stock

  $23.78

  ▼ 4.38%
  Market cap $3.24BP/E 113.86
  $15.1$31.77
• NAMS

  NewAmsterdam Pharma Company N.V. Ordinary Shares

  $25.9

  ▼ 3.32%
  Market cap $3.21BP/E —
  $23.05$42.21
• VKTX

  Viking Therapeutics Inc. Common Stock

  $32.15

  ▼ 5.05%
  Market cap $3.80BP/E —
  $22.96$43.15

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term
  SeekingAlpha · 8/28/2026
• Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030
  SeekingAlpha · 8/21/2026
• Citigroup Maintains Buy on Structure Therapeutics, Lowers Price Target to $97
  Benzinga · 8/7/2026
• Citizens Maintains Market Outperform on Structure Therapeutics, Lowers Price Target to $110
  Benzinga · 8/7/2026
• Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
  Yahoo · 8/6/2026
• The BioRevolution Has Accelerated
  SeekingAlpha · 8/5/2026

• John Joseph Berrios · August 6, 2026 · Grant

  174.6K
• John Joseph Berrios · August 6, 2026 · Grant

  140.8K
• Xichen Lin · August 4, 2026 · Sale

  839 @ $50.03
• Xichen Lin · August 4, 2026 · Sale

  3.1K @ $49.29
• Xichen Lin · August 4, 2026 · Conversion

  3.9K
• Xichen Lin · August 4, 2026 · Option Exercise

  11.8K @ $0.34
• Xichen Lin · August 4, 2026 · Conversion

  11.8K
• FMR LLC · July 22, 2026 · Sale

  16.1K @ $50.07
• FMR LLC · July 22, 2026 · Sale

  1.4K @ $50.07
• Xichen Lin · July 14, 2026 · Sale

  1.6K @ $51.71
• Xichen Lin · July 14, 2026 · Sale

  6.3K @ $50.8
• Xichen Lin · July 14, 2026 · Conversion

  7.9K
• Xichen Lin · July 14, 2026 · Option Exercise

  23.6K @ $0.34
• Xichen Lin · July 14, 2026 · Conversion

  23.6K
• Russell Angus C. · June 17, 2026 · Grant

  39.5K

Institutional Ownership

March 31, 2026

Total shares held

67.34M

Total value held

$3.15B

Institutional holders

195